Background: Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.
introduction
Colorectal cancer (CRC) has a worldwide incidence of 1 million new cases annually and claims the lives of half a million people every year. Curative surgery is attempted at the time of diagnosis for 75% of patients, but up to 50% of all patients will develop incurable recurrences making the 5-year survival rate only 50% [1] .
For 30 years, the mainstay of adjuvant therapy has been 5-fluorouracil (5-FU). 5-FU has several cytotoxic mechanisms among which the inhibition of the enzyme thymidylate synthase (TYMS) is to be the most important. TYMS catalyzes the conversion of deoxyuridylate (dUMP) to deoxythymidylate (dTMP), in which the folate derived cofactor 5,10-methylenetetrahydrofolate (5,10-MTHF) functions as a methyl donor. 5-FdUMP, a metabolite of 5-FU, in combination with 5,10-MTHF inhibits TYMS in an almost irreversibly forming a ternary complex [2] [3] [4] [5] . The lack of intracellular dTMP leads to decreased DNA synthesis, dUMP misincorporation into DNA, and DNA strand breaks followed by cell apoptosis [6, 7] . Experiments have proved that increased intracellular concentrations of reduced folates enhances 5-FU efficacy [2, 4] .
Early clinical studies showed that 5-FU-containing regimes had a beneficial effect on survival [8] ; later combinations of 5-FU with leucovorin (LV, [6R,S]5-formyltetrahydrofolate) were proven superior to other 5-FU regimes [9] [10] [11] .
It has been hypothesized that reduced activity of methylenetetrahydrofolate reductase (MTHFR) could cause an increased intracellular concentration of 5,10-MTHF and augment the cytotoxicity of 5-FU. MTHFR is a pivotal enzyme in folate metabolism that catalyzes the irreversible conversion of 5,10-MTHF to 5-methyltetrahydrofolate, the latter is used in methionine synthesis (and consequently in DNA methylation) and the former is used in nucleotide synthesis.
The MTHFR gene is located on chromosome 1p36.3 and is subject to several single-nucleotide polymorphisms (SNPs homozygous individuals: the MTHFR 677C>T polymorphism induces an Ala-to-Val substitution in the catalytic domain (70% reduction in activity), whereas the MTHFR 1298A>C polymorphism induces a Glu-to-Ala substitution in a regulatory domain (30%-40% reduction) [12] [13] [14] .
Compound heterozygous individuals have a 40%-50% reduction in enzyme activity [13, 14] . Various experimental [15, 16] and clinical studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] have been carried out to test the association between MTHFR polymorphisms and 5-FU treatment effect.
Hitherto available studies focus on two patient populations (Table 1) ; those undergoing treatment for metastatic colorectal cancer [17-20, 22-25, 28] and those undergoing adjuvant therapy before or after surgery [21, 26, 27] . Some studies show a positive effect on survival or response/relapse rates for the 677T allele [17] [18] [19] [20] , others show no effect of MTHFR genotype [21] [22] [23] [24] [25] , and others again show a negative effect of 677T or 1298C alleles [19, [26] [27] [28] . Some studies suggest that the correlation between MTHFR polymorphisms and 5-FU treatment efficacy may only be significant for specific subgroups such as rectal cancer patients [26] or women [28] , but this remains to be confirmed.
We have tested the effect of MTHFR genotype on 5-FU/LV treatment of one of the largest patient samples to date. Our patient sample has only received monotherapy with 5-FU/LV as adjuvant treatment that allows us to determine the effect of genotype on survival and relapse rates specifically during 5-FU/ LV treatment.
patients and methods patients A total of 331 Caucasian patients with stage II-III and 37 patients with a singular excised liver metastasis from colorectal cancer (stage IV), treated at Rigshospitalet (Copenhagen University Hospital) from 1996 to 2003, were eligible for our study. The patients were recruited for testing of molecular prognostic/predictive markers in adjuvant treatment of colorectal cancer. The protocol allowed for collection of formalin-fixed paraffin-embedded (FFPE) tissue.
Patient data were entered and were followed in a database that was updated automatically every 6-12 months with relapse and death rates genotyping Tumor sections were selected from blocks containing approximately 50% tumor tissue.
Three 10 lm sections of each FFPE tumor tissue block were deparaffinized using Estisol 220 and genomic DNA was extracted using the Maxwellä 16 Tissue DNA purification Kit on a Maxwellä 16 instrument (Promega, Denmark) according to the manufacturer's instructions. A NanoDrop ND1000 spectrophotometer (Nanodrop Technologies Inc., Rockland, DE) was used to assess DNA quantity.
DNA samples were diluted to 10 ng per well and analyzed for the MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131) polymorphisms using the fluorogenic 5#-nuclease assay (TaqManÒ SNP Genotyping Assay Made to Order on an ABI 7900 HT, Applied Biosystems, Foster city, CA).
Genotypes were determined in a reaction mix as follows: 25 ll containing 10 ng DNA, 14 ll primer/probe mix with TaqMan Universal PCR Master mix (Applied Biosystems) according to the manufacturer's instructions.
PCR amplification was carried out with an initial step of 95°C for 10 min followed by 40 cycles of 92°C for 15 s and 60°C for 1 min (Applied Biosystems 7900HT Sequence Detection System). The fluorescence profile of each well was measured in an Applied Biosystems 7900HT Sequence Detection System, and the results were analyzed with Sequence Detection Software (SDS 2.3, Applied Biosystems).
Controls were included on each plate. Reproducibility was checked by regenotyping 10% of the cases.
statistical analysis
The primary end points of this study were overall survival (OS), relapse-free survival (RFS), and toxicity. Relapse was defined as the recurrence of disease or death from disease whatever occurred first. OS and RFS were measured from the date of intended curative resection to the date of relapse or death from disease (CRC-related deaths as deaths were actually all due to disease). Patients who were alive or had not relapsed at the last follow-up (30 August 2007) were censored at that time. Toxicity was measured according to the Common Toxicity Criteria (CTC) (National Cancer Institute-Common Toxicity Criteria version 2.0, www.fda.gov/ cder/ cancer/toxicityframe.htm) and maximum toxicity score was used in the statistical analysis.
The associations of clinicopathological characteristics (age, sex, tumor stage, vascular and perineural invasion, tumor grade, bowel obstruction and perforation, and rectal or colon tumor) and MTHFR polymorphisms with RFS and OS were assessed using univariate survival analysis (Kaplan-Meier curves and the log-rank test).
Multiple regression analysis of the independent effects of the two MTHFR polymorphisms on OS and RFS was carried out using the Cox Proportional Hazards model. Assumptions for the Cox analysis were checked for each variable; Cox analysis was only carried out if the variable fulfilled the assumptions. Some variables were registered during treatment (toxicity and performance) contrary to the other variables that were available at entry date. These three variables were only analyzed in regard to OS and RFS in patients alive after completion of treatment (180 days after entry date). Interactions between polymorphisms and the aforementioned clinicopathological variables on RFS and OS were tested by comparing likelihood ratio statistics with or without inclusion of the multiplicative product terms.
The association between MTHFR polymorphisms and overall toxicity was tested using univariate logistic regression and logistic regression analysis adjusted for sex, performance status, days to relapse, and age [29, 30] . Further subgroup analysis of toxicity was carried out according to CTC for: infections, cardiotoxicity, diarrhea, fatigue, mucositis, and nausea/ vomiting.
The associations of MTHFR polymorphisms and clinicopathological factors were analyzed using contingency tables and Fisher's exact tests were suitable.
Linkage disequilibrium between the two MTHFR polymorphisms using D# and r2, haplotype frequencies, and Hardy-Weinberg (HW) equilibrium was calculated using Haploview v4.0 (www.broad.mit..edu/mpg/haploview/).
All reported P values are two sided. All analyses were carried out using the SAS Statistical Package Version 9. Table 2 . Median age was 61 years; the male to female ratio was 1 : 1. Clinically, intestinal perforation was present in 27 cases and bowel obstruction occurred in 49 cases at surgery. There was a followup time of up to 10 years and 169 (51%) had relapsed and 149 (45%) had died at the last follow-up date.
Clinically, performance score, tumor stage, and bowel obstruction were associated to OS and RFS, whereas toxicity was only associated to RFS (Table 3) . Vascular and perineural invasion were also associated to OS and RFS in univariate analysis.
In multiple regression analysis adjusted for covariates, performance score, tumor stage, bowel obstruction, and vascular invasion were associated with OS. Performance score, tumor stage, bowel obstruction, toxicity, and perineural invasion were associated with RFS at the P < 0.05 level (Table  3) . Tumor stage was not associated with OS and RFS when stage IV patients were excluded from analysis, indicating a similar prognosis for stage II and III patients.
MTHFR polymorphisms were not associated with any of the abovementioned clinical or pathological characteristics except toxicity and tumor site. The MTHFR677 TT genotype was overrepresented among rectal cancer patient (11 of 63 patients) compared with colorectal cancer patients (17 of 268) (P = 0.01), such an association was not found for the MTHFR1298 polymorphisms.
MTHFR 677C>T and 1298A>C polymorphisms
MTHFR genotypes were determined for 312 and 309 of 331 cases for the 677C>T and 1298A>C polymorphisms, respectively. Both genotypes were obtained for 290 of 331 cases as the DNA yield or quality was too low in remaining cases. We Annals of Oncology original article found that 10% were 667C>T or 1298A>C homozygous (Table  4) , which is concordant with earlier studies [12-14, 17-29, 31] . Both genotype distributions were in HW equilibrium and reproducibility was 100% for our genotyping.
We analyzed the effect of the MTHFR 677C>T and 1298A>C polymorphisms on OS and RFS after stratification according to genotype both using three groups (MUT/MUT versus MUT/ WT versus WT/WT) and two groups (MUT/MUT versus MUT/WT and WT/WT). We tested subgroups to see if there was an association between genotype and treatment response stratified according to tumor site, sex, tumor stage, tumor grade, or vascular/neuronal invasion. No association was found using Kaplan-Meier curves and the log-rank test in analysis of OS and RFS.
Associations between OS and RFS and the MTHFR polymorphisms are summarized in Figure 1 and Table 3 . Multiple regression analysis of OS and RFS showed similar results after adjusting for covariates (Table 3) . Each clinical variable was checked for interaction with the polymorphisms using the Cox analysis; none was found.
When adjusting for perineural and vascular invasion, we can only analyze a subset of patients due to missing data. Since there is no logical reason why the missing data should introduce systematic bias into our data, we think it is justified to carry out the analysis. Interestingly, excluding perineural and vascular invasion from the Cox model does not change anything regarding polymorphism associations or model fit statistics.
Logistic regression showed that grade 3 and 4 toxicity was overrepresented among patients with the MTHFR 677 CC genotype with an odds ratio (OR) 1.83 [95% confidence interval (CI) 1.13-2.96, P = 0.01]. The association remained significant after adjusting for the aforementioned factors associated with toxicity (OR = 1.83, 95% CI 1.10-3.03, P = 0.01). Subgroup analysis revealed that the 677 CC genotype was particularly associated with grade 3-4 infections (OR = 4.57, 95% CI 1.28-16.38, P = 0.02) and diarrhea (OR = 1.98, 95% CI 1.07-3.65, P = 0.03). After adjustment, the association with infections was borderline significant (OR = 3.90, 95% CI 1.00-15.17, P = 0.05), whereas the association with diarrhea remained significant (OR = 1.99, 95% CI 1.07-3.69, P = 0.03). The MTHFR 1298A>C polymorphism was not associated with any toxicity.
haplotype analysis
There was a strong linkage disequilibrium between the two polymorphisms, in accordance with previous reports [29] , with a D# of 0.97 but r 2 was only 0.2. The three most common haplotypes (C-A, T-A, and C-C) accounted for 99.7% of all haplotypes. None of the haplotypes was associated with OS or RFS; not in the total sample or in any subgroups analyzed.
discussion
The main result of this study is that isolated SNPs in MTHFR probably cannot be used to predict the effect, or rather possible therapeutic failure, of adjuvant 5-FU treatment in colorectal cancer patients. However, we found a statistically significant association between the MTHFR 677C>T polymorphism and toxicity in accordance with earlier studies [29] . Furthermore, the univariate and the multiple regression analysis showed toxicity to be an independent predictor of relapse and death. These findings have to be interpreted with caution and could be the result of multiple testing; applying the Bonferroni correction yields a significance level of 0.005, but this procedure is notorious for being overly conservative.
Subgroup analysis of sex and other clinical variables did not reveal any associations as reported earlier [26, 28] . The associations between the other clinical variables and OS and RFS in our study have been documented before, implying that our population is representative of patients undergoing 5-FU-based adjuvant chemotherapy [30] .
We carried out SNP testing on archived tumor tissue. This could mean that we were unable to correct for the effects of loss of heterozygosity (LOH), which would produce fewer heterozygous individuals than expected. The fact that patient population genotype distribution was in HW equilibrium with genotype frequencies in accordance with previous reports [31] suggests that LOH is of minor importance in our patient population. Being a retrospective study there are limitations. First because of the nature of the disease we could not use a control group. Furthermore, additional tests like immunohistochemistry and MTHFR mRNA determination could not be carried out. Ideally, we would have liked to include more patients, but as demonstrated our study is one of the largest populations studied and treatment wise very homogenous making our results important in this field. Before applying our results, clinically larger studies must be conducted, so smaller survival differences (<10%-15%) can be detected and toxicity results can be confirmed.
An almost unique advantage of our population is that all patients were treated by identical regimes (5-FU/LV) presenting an exceptional opportunity for determining the effect of MTHFR genotypes on 5-FU/LV effect avoiding bias introduced by varying treatment regimes and effects of prior treatments. Monotherapy also means that other drugs do not blemish the analysis of genotype effects with non-related pharmacological mechanisms. At this time, a combination of oxaliplatin and 5-FU/LV is the standard treatment; in a reductionist model, knowing modifying factors for each drug is more informative than knowing modifying factors for the combination therapy alone. The former is only attainable by studying patients treated with a single agent.
Accumulating evidence suggests that MTHFR polymorphisms may not have functional effects in all tissues in vivo, that only the homozygous state predisposes to functional alternations and that polymorphisms only result in altered folate metabolism if the concentration of folate is low [32] [33] [34] [35] . This is, perhaps, the explanation for the lack of clinical relevance for cancer treatment of MTHFR polymorphisms.
General concerns regarding previous studies of the association of these polymorphisms with treatment response include inclusion of pretreated patients making the results difficult to interpret, little statistical power, and inadequate statistical analysis, e.g. lacking multiple regression analysis or consideration of multiple testing. Overall, current clinical studies on the MTHFR polymorphisms have shown varying results with almost equal numbers showing no effect, a positive effect, or a negative effect on survival, response, or relapses. Collectively, our study and previously published data indicate that the clinical significance of studying MTHFR polymorphisms alone is limited: genotyping restricted to these polymorphisms is inadequate to predict outcome in adjuvant 5-FU treatment after complete resection. A role in combination with other relevant SNPs, e.g. TYMS and others, cannot be excluded and has been suggested in other studies [17, 19] .
Our study needs independent confirmation in a similar sized study, but further study of MTHFR polymorphisms should be conducted in combinatorial studies. Combinations of SNPs in a metabolic network are probably better predictors of response than single SNPs. However, combinatorial pharmacogentic studies require considerable sample sizes, well-defined target groups, and clinical relevance making them a daunting endeavor that nonetheless must be pursued. Such research could help to establish prognostic or predictive models that can be validated in large prospective studies.
From a theoretical point of view, there is no reason to think that susceptibility to 5-FU treatment is a monogenic trait since several proteins are involved in the pharmacokinetics and pharmacodynamics of 5-FU (and indeed all drugs). An approach, which combines several of the genes involved in 5-FU metabolism and mechanisms, will yield a better, more logical model for explaining individual variations in 5-FU efficacy.
In conclusion, the MTHFR 677C>T alone may have a weak effect on toxicity but neither polymorphism was predictive of 5-FU efficacy in the adjuvant setting. 
